


Amendments to the Claims

1. (currently amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R₁ is the group (C₄-C₁₂)haloalkyl, -CF₃, allyl, (C₁-C₈)alkylcycloalkyl, or (C₃-C₈)cycloalkyl, ~~substituted benzyl, and (C₂-C₄)alkylaryl, wherein the aryl is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from (C₁-C₁₂)alkyl, (C₂-C₁₂)alkenyl, (C₁-C₁₂)alkoxy, and (C₁-C₁₂)haloalkyl;~~

R₂ is hydrogen;

R₃, R₄, R₅, and R₆, are each independently selected from hydrogen, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, -O-(C₁-C₃ alkyl), COOH, C(O)(C₁-C₃ alkyl), C(O)O(C₁-C₃ alkyl), -CF₃, and halo; or a pharmaceutically acceptable salt thereof.

2. (canceled)

3. (previously presented) A compound according to Claim 1 wherein R₁, is allyl, (C₃-C₄)alkylcycloalkyl, or -CF₃.

4. (canceled)

5. (canceled)

6. (previously presented) The compound of Claim 1 wherein R₅ is the group represented by chloro, bromo or CF₃.

7. (currently amended) A compound selected from the group consisting of:


- 3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid allylamide;
- 3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide;
- ~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 2-methyl-benzylamide;~~
- ~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 3-methyl-benzylamide;~~
- ~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 4-methyl-benzylamide;~~
- ~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;~~
- ~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;~~
- ~~3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid phenethylamide;~~
- 3-Oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide;
- 6-Chloro-3-oxo-3*H*-benzo[d]isothiazole-2-carboxylic acid cyclohexylamide; ~~and~~

8. (canceled)

9. (currently amended) A pharmaceutical formulation comprising a benzisothiazole-3(2*H*)-one compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

10-11. (canceled)

12. (currently amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein R_1 , R_6 are defined as in claim 1



I

wherein:

R₁ is the group (C₄-C₁₂)haloalkyl, -CF₃, allyl, (C₁-C₈)alkylcycloalkyl, or (C₃-C₈)cycloalkyl, substituted benzyl, and (C₂-C₄)alkylaryl, wherein the aryl is optionally substituted and the benzyl is substituted with 1 to 3 groups independently selected from (C₁-C₁₂)alkyl, (C₂-C₁₂)alkenyl, (C₁-C₁₂)alkoxy, and (C₁-C₁₂)haloalkyl;

R₂ is hydrogen;


R₃, R₄, R₅, and R₆, are each independently selected from hydrogen, (C₁-C₄)alkyl, (C₂-C₄)alkenyl, -O-(C₁-C₃alkyl), COOH, C(O)(C₁-C₃alkyl), C(O)O(C₁-C₃alkyl), -CF₃, and halo; or a pharmaceutically acceptable salt thereof;
formulated for the treatment of the effect of elevated hepatic lipase activity
hypercholesterolemia, hyperlipidemia, or atherosclerosis.

13-15. (canceled)

16. (currently amended) The method of claim ~~40~~18 wherein the benzisothiazole-3(2H)-one compound is formulated with a with a pharmaceutically acceptable carrier or diluent.

17. (canceled)

18. (currently amended) A method of treating hypercholesterolemia, hyperlipidemia, or atherosclerosis in a mammal in need thereof comprising administering using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R₁-R₆ are as defined in claim 1



I

or a pharmaceutical acceptable salt thereof.